Latest Safety News

LTR Pharma Limited (ASX, LTP) reported significant progress in FY25, advancing its novel intranasal treatments for erectile dysfunction and expanding its commercial footprint in Australia and the US. The company secured key partnerships and capital raises, positioning itself for regulatory milestones and global market entry.

Virgin Australia has delivered a strong FY25 performance with pro forma underlying NPAT up 27.8%, meeting prospectus targets, while reaffirming its FY26 outlook amid operational improvements and fleet expansion.

PYC Therapeutics has reported promising safety data from the initial phase of its clinical trial for PYC-003, an RNA therapy targeting the root cause of Polycystic Kidney Disease. The findings, presented at the ANZSN conference, highlight the drug’s tolerability in healthy volunteers, paving the way for further clinical development.

Memphasys Limited reported a net loss of AUD 4.94 million for FY25 while accelerating commercial efforts for its Felix System and advancing its RoXsta diagnostics platform.

PARKD Limited reported a remarkable 218% increase in revenue to $11.83 million for FY25, driven by key construction projects and new licensing agreements. The company narrowed its loss by 74%, signaling progress in commercialising its modular construction technology.

Mesoblast Limited has reported its FY2025 results, highlighting the FDA approval and US commercial launch of Ryoncil, its first mesenchymal stromal cell therapy, alongside a $102.1 million net loss and $161.6 million in cash reserves.

Bhagwan Marine Limited has delivered a strong first year as an ASX-listed company with record net revenue and EBITDA growth, alongside its inaugural dividend declaration. The company is advancing growth in offshore energy, subsea, ports, and defence sectors while investing in innovation and fleet expansion.

Metro Mining Limited delivered a remarkable turnaround in the first half of 2025, posting record bauxite shipments and a $119.8 million net profit after tax, reversing prior losses and impairments.

Bhagwan Marine Limited has reported record financial results for FY25, driven by strong growth across its core marine services and new sectors. The company also declared its inaugural fully franked dividend, signaling confidence in its strategic direction.

RemSense Technologies posted a 107% revenue surge to $3.44 million in FY2025 alongside a 67% reduction in net loss, driven by operational efficiencies and strong client demand. The company achieved positive cash EBITDA and strengthened its global footprint with Tier 1 clients.

Noxopharm Limited reported a 36.5% increase in its annual loss to $4.88 million as it progressed preparations for its SOF-SKN™ clinical trial and secured $2.6 million through convertible notes. The biotech continues to invest heavily in its inflammation and oncology drug pipeline while managing liquidity and strategic partnerships.

Wellard Ltd posts a net profit turnaround in FY2025 despite fleet downsizing, sells its last vessel, and plans to delist from the ASX while returning substantial capital to shareholders.